Literature DB >> 12637533

Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance.

Kerstin Wolk1, Stefanie Kunz, Nigel E A Crompton, Hans-Dieter Volk, Robert Sabat.   

Abstract

Patients after polytrauma, burns, or septic shock frequently develop a life-threatening immunodeficiency. This state is associated with specific functional alterations of monocytic cells. We previously proposed endotoxin tolerance, the monocyte state after acute response to lipopolysaccharide, as a respective model system. One major feature in both the clinical situation and the in vitro model is the dramatic down-regulation of monocyte major histocompatibility complex (MHC) class II surface expression, which is associated with impaired antigen presentation capacity. This study focused on the mechanisms behind reduced MHC class II expression in endotoxin tolerance. Endotoxin priming provoked a decrease of monocyte intracellular MHC class II. It also led to a reduced expression of the chaperonic invariant chain and to an inhibited synthesis of the major lysosomal enzyme for final cleavage of the invariant chain going along with a relative accumulation of p10. The expression of HLA-DM necessary for loading MHC class II with antigenic peptide was also decreased. Additionally, reduced export of MHC class II alphabeta complexes to the cell surface was observed. The down-regulation of HLA-DR, invariant chain, and HLA-DM was regulated at the mRNA level and may be the consequence of reduced class II transactivator expression observed in this study. The simultaneous interference at different regulatory levels may explain the uniquely strong and long lasting MHC class II down-modulating effect of endotoxin priming compared with transforming growth factor-beta and interleukin-10. These results not only contribute to a better understanding of experimental endotoxin tolerance but may also give rise to new therapeutics for temporary immunodeficiency and, conversely, for MHC class II-dependent diseases such as autoimmunity and transplant rejection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637533     DOI: 10.1074/jbc.M207714200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Expression of triggering receptor on myeloid cell 1 and histocompatibility complex molecules in sepsis and major abdominal surgery.

Authors:  Nestor González-Roldán; Eduardo Ferat-Osorio; Rosalía Aduna-Vicente; Isabel Wong-Baeza; Noemí Esquivel-Callejas; Horacio Astudillo-de la Vega; Patricio Sánchez-Fernández; Lourdes Arriaga-Pizano; Miguel Angel Villasís-Keever; Constantino López-Macías; Armando Isibasi
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

2.  Antigen capture of Porphyromonas gingivalis by human macrophages is enhanced but killing and antigen presentation are reduced by endotoxin tolerance.

Authors:  Manoj Muthukuru; Christopher W Cutler
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

3.  IRAK-M modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells.

Authors:  Tyler S Cole; Min Zhang; Theodore J Standiford; Michael Newstead; Jay Luther; Jiajie Zhang; Chun-Chia Chen; John Y Kao
Journal:  Immunol Lett       Date:  2012-03-28       Impact factor: 3.685

4.  Decreased expression of HLA-DQ and HLA-DR on cells of the monocytic lineage in cystic fibrosis.

Authors:  Thomas P Hofer; Marion Frankenberger; Irene Heimbeck; Dorothe Burggraf; Matthias Wjst; Adam K A Wright; Maria Kerscher; Susanne Nährig; Rudolf M Huber; Rainald Fischer; Loems Ziegler-Heitbrock
Journal:  J Mol Med (Berl)       Date:  2014-08-23       Impact factor: 4.599

5.  Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production.

Authors:  Andrea Broad; John A Kirby; David E J Jones
Journal:  Immunology       Date:  2006-10-11       Impact factor: 7.397

6.  Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients.

Authors:  Neil E Alexis; Marianne S Muhlebach; David B Peden; Terry L Noah
Journal:  J Cyst Fibros       Date:  2005-12-13       Impact factor: 5.482

7.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Authors:  Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

Review 8.  Rebuilding immunity in cancer patients.

Authors:  Stanimir Vuk-Pavlovic
Journal:  Blood Cells Mol Dis       Date:  2007-09-10       Impact factor: 3.039

9.  Monocyte human leukocyte antigen-DR expression-a tool to distinguish intestinal bacterial infections from inflammatory bowel disease?

Authors:  Wolfgang Tillinger; Ruth Jilch; Thomas Waldhoer; Walter Reinisch; Wolfgang Junger
Journal:  Shock       Date:  2013-08       Impact factor: 3.454

10.  Altered inactivation of commensal LPS due to acyloxyacyl hydrolase deficiency in colonic dendritic cells impairs mucosal Th17 immunity.

Authors:  Brian M Janelsins; Mingfang Lu; Sandip K Datta
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.